Disease · MONDO_0001330
Comparisons in its trials21
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 21
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pilocarpine HCl Ophthalmic Solution vs Vehicle: deaths from any cause | 0 of 163 | 0 of 160 | 323 | NCT03804268 | Trial comparisons |
| Pilocarpine HCl Ophthalmic Solution vs Vehicle: serious adverse events | 0 of 163 | 0 of 159 | 322 | NCT03804268 | Trial comparisons |
| CSF-1 vs Vehicle: Percentage of Subjects With a ≥ 3-line Gain in BDCVA (Best Distance-Corrected Visual Acuity) at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8, 1 Hour Post-Dose 1. | 60 of 155 | 26 of 154 | 309 | NCT04599933 | Trial comparisons |
| CSF-1 vs Vehicle: Percentage of Subjects With a ≥ 3-line Gain in BDCVA at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8 at 1 Hour Post-Dose 2 | 74 of 155 | 24 of 154 | 309 | NCT04599933 | Trial comparisons |
| CSF-1 vs Vehicle: Percentage of Subjects With a ≥ 3-line Gain in BDCVA at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8 at 2 Hours Post-dose 2 | 60 of 155 | 23 of 154 | 309 | NCT04599933 | Trial comparisons |
| CSF-1 vs Vehicle: deaths from any cause | 0 of 155 | 0 of 154 | 309 | NCT04599933 | Trial comparisons |
| CSF-1 vs Vehicle: Percentage of Subjects With a ≥ 3-line Gain in BDCVA at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8 at 2 Hours Post-Dose 1 | 61 of 155 | 26 of 154 | 309 | NCT04599933 | Trial comparisons |
| CSF-1 vs Vehicle: serious adverse events | 0 of 155 | 1 of 154 | 309 | NCT04599933 | Trial comparisons |
| CSF-1 vs Vehicle: Percentage of Subjects With a ≥ 3-line Gain in BDCVA at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8 at 2 Hours Post-dose 2 | 71 of 154 | 29 of 150 | 304 | NCT04599972 | Trial comparisons |
| CSF-1 vs Vehicle: Percentage of Subjects With a ≥ 3-line Gain in BDCVA at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8 at 1 Hour Post-Dose 2 | 80 of 154 | 25 of 150 | 304 | NCT04599972 | Trial comparisons |
| CSF-1 vs Vehicle: Percentage of Subjects With a ≥ 3-line Gain in BDCVA (Best Distance-Corrected Visual Acuity) at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8, 1 Hour Post-Dose 1. | 64 of 154 | 32 of 150 | 304 | NCT04599972 | Trial comparisons |
| CSF-1 vs Vehicle: deaths from any cause | 0 of 153 | 0 of 151 | 304 | NCT04599972 | Trial comparisons |
| CSF-1 vs Vehicle: Percentage of Subjects With a ≥ 3-line Gain in BDCVA at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m. | 62 of 154 | 31 of 150 | 304 | NCT04599972 | Trial comparisons |
| CSF-1 vs Vehicle: serious adverse events | 0 of 153 | 1 of 151 | 304 | NCT04599972 | Trial comparisons |
| AGN-190584 vs Vehicle: deaths from any cause | 0 of 114 | 0 of 116 | 230 | NCT04983589 | Trial comparisons |
| AGN-190584 vs Vehicle: serious adverse events | 0 of 114 | 0 of 116 | 230 | NCT04983589 | Trial comparisons |
| CSF-1 vs Vehicle: Number of Participants With Treatment Emergent Adverse Events. | 43 of 118 | 16 of 60 | 178 | NCT05393895 | Trial comparisons |
| CSF-1 vs Vehicle: deaths from any cause | 0 of 118 | 0 of 60 | 178 | NCT05393895 | Trial comparisons |
| CSF-1 vs Vehicle: serious adverse events | 0 of 118 | 0 of 60 | 178 | NCT05393895 | Trial comparisons |
| AGN-190584 vs Vehicle: Number of Participants With Adverse Events | 32 of 43 | 8 of 43 | 86 | NCT04837482 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001330/comparisons